Acute Kidney Injury After Cardiac Surgery

Overview

PrimECC is a colloid priming solution for cardiopulmonary bypass/ extracorporeal circulation (ECC) based on Ringers Lactate, supplmeneted with Dextran 40 and Dextran 1. In a previous RCT comparing PrimECC with crystalloid priming fluid, patients in the PrimECC group experienced less hemolysis, less tubular cell injury and beneficial effect on the fluid balance. This study will investigate if, in a population at high risk of acute kidney injury (AKI), priming the ECC circuit with PrimECC instead of crystalloid solution will lead to a reduction of postoperative AKI. The hypothesis is that PrimECC, compared to crystalloid prime, will reduce postoperative AKI. The study is a Swedish multicenter, double-blinded, randomized, controlled clinical trial. The trial will include 366 patients aged ≥18 years, scheduled for cardiac surgery with cardiopulmonary bypass, with an "Acute kidney injury risk score" ≥30% according to Birnie et al. (2014). The primary outcome of the study is the incidence of postoperative AKI of any stage according to the KDIGO creatinine criteria (serum-creatinine increase ≥ 27 μmol/l within 48 h or ≥ 50 % increase from baseline) within 96 hours after arrival to the ICU. Secondary outcomes are between-group differences in hemolysis, tubular cell injury (NAG-excretion), estimated GFR, and incidence of AKI of different stages according to the KDIGO creatinine criteria. In addition, differences in CNS (Tau, NFL, NSE, and S100B) and cardiac (TNT/TNI) injury markers will be investigated.

Full Title of Study: “Acute Kidney Injury After Cardiac Surgery; A Prospective Randomized Study of Dextran Based and Crystalloid Priming Solutions (PRIMING II Trial)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Triple (Participant, Care Provider, Investigator)
  • Study Primary Completion Date: August 31, 2023

Interventions

  • Device: Colloid priming solution for ECC circuit
    • Prospective, multi-center, double-blinded, randomized, controlled clinical trial
  • Device: Standard priming solution for ECC circuit
    • Prospective, multi-center, double-blinded, randomized, controlled clinical trial

Arms, Groups and Cohorts

  • Experimental: Colloid priming solution for ECC circuit
    • Priming of ECC circuit with approximately 1200 mL PrimECC.
  • Active Comparator: Standard priming solution for ECC circuit
    • Priming of ECC circuit with approximately 1200 mL standard priming solution (crystalloid solution with or without mannitol addition as per routine of the participating clinic).

Clinical Trial Outcome Measures

Primary Measures

  • Incidence of post-operative AKI
    • Time Frame: Within 96 hours after ICU arrival
    • Incidence of postoperative AKI of any stage according to the KDIGO creatinine criteria (serum-creatinine increase ≥ 27 μmol/l within 48 hours or ≥ 50 % increase from baseline)

Secondary Measures

  • NAG excretion
    • Time Frame: 1 hour post initiation of ECC, at 1 hour after disconnection from ECC and 24 hours after disconnection from ECC.
    • NAG-excretion (U-NAG/U-creatinine)
  • eGFR
    • Time Frame: Pre-operative and within 96 hours after ICU arrival
    • pre-operative (day before surgery) compared to the highest post-operative value Measured value of pre-operative eGFR compared to the highest post-operative value within 96 hours after ICU arrival, calculated using the CKD-EPI formula
  • Incidence of AKI
    • Time Frame: Within 96 hours after ICU arrival
    • Incidence of AKI of different stages according to the KDIGO creatinine criteria
  • Hemolysis
    • Time Frame: Pre-operative (after induction of anesthesia) and at 1 hour post initiation of ECC, 1 hour after disconnection from ECC and at 24 hours after disconnection from ECC.
    • Hemolysis measured as free hemoglobin (PfHb)
  • CNS injury markers
    • Time Frame: Pre-operative (after induction of anesthesia), 1 hour after disconnection from ECC and at 24 hours after disconnection from ECC.
    • Measured concentrations of CNS injury markers Tau, NFL, NSE, and S100B
  • Myocardial injury markers
    • Time Frame: Pre-operative (after induction of anesthesia) and at 1 hour after discontinuation of ECC and 24 hours after disconnection from ECC.
    • Measured concentrations of myocardial injury markers TnI or TnT. TnI or TnT is chosen according to institutional standard

Participating in This Clinical Trial

Inclusion Criteria

  • Has signed and dated the EC approved informed consent – Subject is ≥ 18 years of age – Requires elective or urgent (non-emergency) cardiac procedure requiring the use of ECC. – Preoperative "Acute kidney injury risk score" ≥30%, found at http://cardiacsurgeryleicester.com/our-research/acute-kidney-injury-risk-score-calcula tor/ Exclusion Criteria:

  • Unable to give informed consent – Known bleeding disorder – Known intolerance or contraindication to dextran – Acute Surgery (requires emergency cardiac procedure/surgery) – Currently using an antithrombotic medication which has not been discontinued per institution protocol – Malignancy; Surgery within 5 years or ongoing antitumoral treatment – Has ongoing sepsis or endocarditis – Requires pre-operative dialysis

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • XVIVO Perfusion
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Lukas Lannemyr, MD,PhD, Principal Investigator, Sahlgrenska University Hospital, Sweden

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.